Tharimmune Unveils Promising Data on New Biologic Treatments

Tharimmune, Inc., a clinical-stage biotechnology company, recently announced preclinical data showcasing two innovative multispecific biologics, HS1940 and HS3215, developed with their EpiClick™ Technology. These biologics represent significant expansions in their pipeline, targeting cancer treatment and addressing unmet medical needs.

HS1940 simultaneously targets PD-1 and VEGF, potentially enhancing treatment options across various cancers. This biparatopic biologic demonstrates high binding affinity and smaller size, facilitating better tumor penetration. Tharimmune plans to optimize its characteristics and initiate further studies in 2025.

Simultaneously, HS3215 targets HER2 and HER3 receptors, aiming to disrupt cancer signaling and overcome resistance. Tharimmune is conducting preclinical studies and plans to advance HS3215 into clinical trials.